Skip to main content
Premium Trial:

Request an Annual Quote

Norak Changes Name to Xsira, Plans Sale of Fluorescent Assay Technology

NEW YORK, Jan. 3 (GenomeWeb News) - Norak Biosciences said this week that it has changed its name to Xsira Pharmaceuticals to reflect its transition from a platform technology company to a product development company.


As part of the change, Norak also plans to sell all aspects of its business related to Transfluor, its flagship fluorescent assay technology for screening G-protein coupled receptors.


Terry Willard, executive vice president of Xsira, told GenomeWeb News' sister publication Inside Bioassays that the company doesn't yet have a buyer for Transfluor, but that several companies are interested.

The Scan

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.

Study Tracks Outcomes in Children Born to Zika Virus-Infected Mothers

By following pregnancy outcomes for women with RT-PCR-confirmed Zika virus infections, researchers saw in Lancet Regional Health congenital abnormalities in roughly one-third of live-born children.

Team Presents Benchmark Study of RNA Classification Tools

With more than 135 transcriptomic datasets, researchers tested two dozen coding and non-coding RNA classification tools, establishing a set of potentially misclassified transcripts, as they report in Nucleic Acids Research.

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.